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NONINVASIVE AND TARGETED INTERRUPTION OF THE BLOOD BRAIN 
BARRIER FOR DRUG DELIVERY USING FOCUSED ULTRASOUND IN THE 
TREATMENT OF CNS DISORDERS 
 
 
ZIMENG GAO 
 
ABSTRACT 
 
Despite the prevalence of CNS disorders, treatment options for CNS disorders fall 
woefully behind treatment options for other systemic disorders. This is due to the 
presence of the blood brain barrier (BBB) acting as an obstacle, preventing foreign 
substances from entering the brain. A newly developed and innovative biomedical 
procedure attempts to bypass the BBB in the delivery of therapeutics by using focused 
ultrasound (FUS) to disrupt and temporarily open the BBB. The use of FUS-facilitated 
BBB opening is able to target specific tissue for noninvasive, localized BBB penetration.  
As the technique is experimental and in it’s nascent stage of development, there 
are only a few studies that investigate its abilities in delivering treatments directly to the 
brain. The studies involve delivery of large, hydrophilic molecules that traditionally 
would not be able to bypass the BBB and enter the brain, and analysis of CNS 
concentrations of the molecules after FUS treatment, as well as the therapeutic successes.  
Results of FUS the studies are promising and the results demonstrate that the 
procedure is able to significantly increase drug concentrations in the brain, increase 
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survival rates in animal models, decrease tumor growth, and decrease tumor margins and 
volume. The potential and power of FUS should be further explored as the future of CNS 
disorder treatments.  
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INTRODUCTION 
!
Central Nervous System Disorders ! Despite!incredible!advances!in!modern!medicine,!biotechnology,!research,!and!pharmaceuticals,!disorders!of!the!central!nervous!system!(CNS)!remain!one!of!the!most!elusive!fields!of!treatment!and!one!of!the!most!prevalent!afflictions!with!the!highest!rates!of!death.!CNS!disorders!can!be!neurologic!or!psychiatric,!and!encompass!a!wide!range!of!diseases!affecting!either!the!brain!or!the!spinal!cord,!including,!but!not!limited!to!aliments!such!as:!epilepsy,!Alzheimer’s!disease,!Huntington’s!disease,!Parkinson’s!disease,!schizophrenia,!multiple!sclerosis,!and!brain!cancer!(National!Institute!of!Neurological!Disorders!and!Stroke,!2014).!! Table!1!presents!summary!statistics!for!five!of!the!most!prevalent!CNS!disorders!in!the!United!States,!afflicting!a!staggering!number!of!9,050,000!total!patients!(Brain!Institute,!2014).!!According!to!the!U.S.!Department!of!Health!and!Human!Services,!Alzheimer’s!and!Parkinson’s!disease!were!respectively!the!6th!and!14th!leading!causes!of!deaths!in!the!United!States!in!2011,!and!brain!cancer!was!the!8th!leading!cause!of!cancerMrelated!deaths!(Hoyert,!2012).!!!
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Table 1. Summary statistics for five of the most prevalent CNS disorders in the 
United States (Table taken from Hoyert, 2012). 
Condition Number of Patients Diagnosed in 
United States 
Number of deaths in 
2011 
Alzheimer’s disease 4,500,000 84,691 
Epilepsy 2,300,000 50,000 
Parkinson’s disease 1,500,000 23,107 
Multiple sclerosis 400,000 2,844 
Tumor (brain and NS) 350,000 14,492 
Total 9,050,000 175,134 !! As!demonstrated!in!Table!1,!the!need!for!increased!therapeutic!potency!for!CNS!disorders!is!real,!but!pharmaceutical!developmental!progress!is!severely!hindered!by!the!physiological!structure!of!the!CNS.!
 
Blood Brain Barrier  
The existence of the tight junctions between endothelial cells in the cerebral 
vasculature creates the blood brain barrier (BBB), a tight protective seal against the entry 
of proteins into the brain (Barrett, 2012). The BBB serves to maintain the environment of 
the brain and acts as a protective mechanism against the various circulating pathogens 
and foreign bodies in the blood (University of Texas Medical School, 2013).  
At a cellular level, the BBB (seen in Figure 1) is comprised of cerebral 
endothelial cells joined together by tight junctions (Abbott, 2009). Tight junctions are 
created by a network of transmembrane proteins such as claudin and occludin, which are 
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anchored to the actin of the cytoskeleton on each protein end, creating a tight seal 
between the two plasma membranes. Endothelial tight junctions, as well as a basement 
membrane directly under the endothelial cells, protect the cerebral vasculature. In 
addition, pericytes are also present intermittently along the capillaries, with astrocytic 
processes surrounding the entire BBB structure. While complex, these protective 
structures serve to prevent foreign particles from penetrating the brain.  
 
Figure 1. Cellular structure of the blood brain barrier. The blood brain barrier is 
comprised of endothelial cells linked by tight junctions, a basement membrane, as well as 
the occasional pericyte (Figure taken from Abbott, 2009). 
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The efficacy of the BBB in preventing hydrophilic protein infiltration into the 
brain can be demonstrated by the constant intravenous infusion of urea and comparing 
the relative concentrations of urea in the tissues of the muscle, brain, and cerebrospinal 
fluid (Figure 2). In this figure, it can be seen that the concentration of urea in the muscle 
tissues increases rapidly in the minutes following the beginning of urea infusion, and then 
eventually equilibrates with the plasma urea concentration after an hour of constant 
infusion. However, while the brain and cerebrospinal fluid concentrations of urea rise 
slightly during the course of infusion, their concentrations never equilibrate with that of 
the plasma. The existence of the tight junctions of the BBB prevents the entry of urea into 
the brain, effectively creating a barrier that discourages change to the local environment.  
Despite its necessary defensive properties, the BBB proves to be a cumbersome 
obstacle to drug delivery targeted to the brain and reduces the efficacy of such drugs 
immensely.  
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Figure 2. Infiltration of urea into various tissues. Constant intravenous infusion of 
urea demonstrates the relative impenetrability of the brain and cerebrospinal fluid (CSF) 
(Figure taken from Barrett, 2012). !!
Current CNS Disorder Therapeutic Options 
 The current development of therapeutics for CNS disorders lags woefully behind 
therapeutics for other system disorders, as the existence of the BBB creates a bottleneck 
against many potentially promising neurotherapeutics (Pardridge, 2005). The BBB 
proves selectively permeable for small (<400 Da), lipophilic molecules, and demonstrates 
exponential impermeability against molecules with increased surface area (Fischer, 
Gottschlich, & Seelig, 1998).  In consideration of the physical limitations posed by the 
existence of the BBB, most therapeutics in the form of synthesized proteins, monoclonal 
antibodies (MAb), and enzymes are excluded from passage in the CNS (Pardridge, 2007). 
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While a given indication might prove efficacious in vitro,!there!is!no!delivery!system!capable!of!transporting!the!drug!past!the!BBB!in!an!adequate!amount.!
 A look at the currently approved therapeutics for the treatment of CNS disorders 
such as depression (Table 2), Alzheimer’s disease (Table 3), and schizophrenia (Table 4) 
reveals a trend of developed therapeutics with a low molecular weight, lack of ionization 
at physiological pH, and high lipophilicity—qualifications that severely limit the options 
available for developing CNS disorder therapeutics. Strategies of temporarily 
manipulating the BBB include transient osmotic opening of the BBB, utilizing chemical 
transporters to increase endocytosis or uptake of drugs, and biodegradable implants—
however, each method has proven to have limited success due to toxicity and safety 
concerns, or issues relating to low efficacy (Misra, 2003).  
  
Table 2. Approved drugs for the treatment of depression and their physical 
characteristics (Table taken from Banks, 2009).  
API MW (Da) log p 
Bupropion 276.2 3.7 
Duloxetine 333.9 5.0 
Escitalopram 324.4 4.2 
Paroxetine 329.4 3.4 
Sertraline 306.3 5.6 
Venlafaxine 319.2 3.2 
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Table 3. Approved drugs for the treatment of Alzheimer’s disease and their physical 
characteristics (Table taken from Banks, 2009). 
API MW (Da) log p 
Donepezil 379.4 4.1 
Galantamine 287.4 2.4 
Memantine 179.3 2.2 
Rivastigmine 250.3 2.6 
Tacrine 198.3 2.3 
 
 
Table 4. Approved drugs for the treatment of schizophrenia and their physical 
characteristics (Table taken from Banks, 2009). 
 
API MW (Da) log p 
Aripiprazole 448.4 4.5 
Chlorpromazine 318.9 5.5 
Clozapine 326.8 2.5 
Haloperidol 375.9 4.4 
Risperidone 410.5 2.7 
Olanzapine 312.4 2.2 
Quetiapine 383.5 2.3 
Ziprasidone 412.9 3.8 
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 Another method for improving drug uptake is to create a prodrug precursor for the 
active compound (Han, 2000). A prodrug is an inactive form of the active species, and 
would be specifically biochemically designed to improve the lipophilicity through the 
addition of a nonpolar particle to the compound in order to increase its chances of 
bypassing the BBB. Once past the BBB, the nonpolar portion would be cleaved and the 
active compound released. Unfortunately, while the creation of the prodrug increases 
mobility of the compound across the BBB, it also increases uptake into other tissues, 
creating negative and unintended side effects. Additionally, prodrugs have the potential 
to undergo alternative cleavage and activation pathways, resulting in toxic metabolites 
that cause damage to surrounding tissue or tumorigenesis (Nelson, 1982). 
 Direct intracranial injection, an alternative method of CNS therapeutic delivery, 
has unfortunately been met with little success. The rapid clearance rate of cerebral fluids 
and the limited diffusion prevent effective drug distribution, and the invasive procedure 
of intracranial injection creates tissue damage at the area of therapeutic delivery 
(Krewson, Klarman, & Saltzman, 1995).  
 
Focused Ultrasound 
 Focused ultrasound (FUS) is a procedure that utilizes the energy of supersonic 
waves to create local disturbances deep within the tissue without damaging the tissue 
surface. The physiological effects and biomedical potential of FUS were first explored by 
Lynn and colleagues in 1942 (Lynn, 1942). Lynn’s research demonstrates that the effects 
of the FUS are directly correlated with physical parameters such as pulse length and 
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frequency, and that FUS is capable of delivering localized and directed damage to tissue 
through the adjustment of the stimulating beam’s focal point. His results also show 
minimal damage to the tissue in the path of the FUS beam directly above the beam’s 
focal point, as well as in the tissue immediately surrounding the focal point (Table 5).  
 
Table 5. Beef liver changes produced by Focused Ultrasound. The localized and 
contained effects of FUS can be observed. The surface tissue in the direct path of the 
stimulating beam remains free from damage, and the focusing effects of the beam is most 
effective when pulse length is minimized and power maximized (Table taken from Lynn, 
1942). !
  
  
 FUS’s ability to cause rapid coagulation necrosis in tissue has been used 
effectively in clinical cases against diseased tissue, such as in treatment of cancer (Blana, 
2004). In a 5-year longitudinal study involving 146 patients with Stage T1-T2N0M0 
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prostate cancer, Blana was able to demonstrate the capability of FUS in the localized 
destruction of the targeted tissue, without damage to neighboring areas.  
 In a safety and efficacy study conducted by McDannold on nonhuman primates, 
he was able to establish that BBB opening using FUS did not result in cerebral tissue 
damage, or have visual or behavior effects on the rhesus macaques. All the monkeys 
recovered completely after BBB opening, supporting the safety of this procedure 
(McDannold, 2013). The noninvasive procedure and low-morbidity risk of the FUS 
makes it an invaluable tool in treating patients unable to undergo dramatic and invasive 
surgical options.  
 The shortcomings of current CNS therapeutic options combined with the 
advantages of the FUS technique contribute to making FUS a prime candidate for the 
future of CNS therapeutic treatment. 
 
Microbubble Enhancement  
 The efficacy of the drug delivery aided by FUS can be further enhanced by the 
addition of microbubbles, synthesized shell structures with short half-lives (Liu, 2014). 
Current microbubble designs incorporate materials such as albumin, phospholipids, or 
polymers as its biodegradable shell, which allow the microbubbles to be more stable 
(Frinking, 2000). Microbubbles are routinely used to perfuse organs for diagnostic 
purposes, due to their ability to enhance the contrast between the vasculature and 
neighboring tissues during ultrasound imaging. Commercial microbubbles are typically 
2-4 µm in size and have a life span of 5-10 minutes.  
!11 
 When used in conjunction with FUS, microbubbles have been found to enhance 
the spread of the drug at its delivery target. Microbubbles, when stimulated by 
ultrasound, can interact with the local environment through stable or inertial cavitation 
(Figure 3). Through stable cavitation, the energy of the FUS causes repeated microbubble 
expansion and contraction of the microbubble, the pressure of which, when applied to 
cell surfaces, causes changes in cell permeability through adjustments in ion channel 
permeability (Sboros, 2008). Through inertial cavitation, the energy of the FUS causes 
such rigorous microbubble expansion and contraction that it implodes, agitating the local 
cell membranes enough to increase permeability due to the release of shock waves and 
local heat (Dalecki, 2004).  
 
Figure 3. Schema of acoustic pressures and their effects on microbubble behavior. 
Stable cavitation is the constant but stable oscillation in size of the microbubble, and 
inertial cavitation is the extreme agitation of a microbubble using acoustic pressures such 
that it collapses and generates shock waves (Figure taken from Lentacker, 2009). 
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 The size of the microbubbles and the frequency of the FUS were found to be 
critical factors in the opening of the BBB. In a study conducted by Choi, microbubbles 
with larger diameters, resonated at the same frequencies, were found to be the more 
effective in BBB penetration than smaller microbubbles (Choi, 2010). This observation is 
most likely due to the higher mechanical stress larger microbubbles place on cell 
membranes compared to smaller microbubbles.  
 With the combinatory use of microbubbles in the CNS vasculature and FUS, the 
efficacy of BBB opening can increase significantly.  
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FUS TECHNOLOGIES ! !! While!FUS!has!been!shown!to!noninvasively!and!locally!penetrate!the!BBB,!the!procedure!is!still!very!novel,!mostly!conducted!in!the!last!three!years,!and!research!on!its!potential!in!relation!to!the!treatment!of!CNS!disorders!is!still!in!its!nascent!stages.!Very!few!experiments!have!been!conducted!that!does!not!simply!prove!that!FUS!is!able!to!facilitate!the!temporary!opening!of!the!BBB,!but!actually!attempts!to!locally!deliver!medications!to!the!brain!and!assess!the!success!of!the!delivered!therapeutics!for!the!given!indication.!The!goal!of!this!study!is!to!assemble!and!examine!the!range!of!experiments!completed!that!has!aimed!to!deliver!a!therapeutic!substance,!one!that!would!have!been!unable!to!penetrate!the!BBB!by!traditional!methods!of!administration,!to!the!brain!in!treatment!of!a!CNS!disorder.!This!study!organizes!experiments!by!intended!indication!in!order!to!discuss!current!methodologies!and!to!assess!the!feasibility,!efficacy,!and!future!potential!of!the!novel!and!experimental!procedure!of!FUSMfacilitated!penetration!of!the!BBB!in!the!delivery!of!CNS!disorder!therapeutics.!
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PUBLISHED STUDIES 
 
 The use of FUS has been shown to increase the permeability of the BBB to 
proteins and other hydrophilic components. One of the prime advantages of FUS over 
other therapeutic techniques is its localized and reversible effect on the BBB, which is in 
stark contrast to previous methods of intracranial injections or removal of skull pieces, an 
invasive and high-risk method of drug administration (Hynynen, 2003; Jordao, 2010).  
 FUS contains the BBB to a circumscribed area by centering the ultrasonic beam 
onto the region of the brain for which the therapeutic agents are formulated. 
Administration of microbubbles prior to FUS treatment further improves the efficacy of 
BBB opening by minimizing damage to neighboring tissues and containing the damages 
to the cerebral vasculature (Choi, 2008; Hynynen 2003). The current studies addressing 
the usage of this technique demonstrates its delivery of a range of therapeutics in the 
treatment of a myriad of CNS disorders.  
 
Glioblastoma 
 Glioblastoma multiforme (GBM) is a common and destructive form of brain 
tumor with a median survival length of 4 ½ months without treatment (Johnson, 2012). 
Incredibly fast-acting and aggressive, GBM is pathologically characterized by necrotizing 
tissues surrounded by anaplastic cells, which are in turn nurtured by hyperplastic blood 
vessels. GBMs form very quickly in the cerebral white matter, and can be visualized by a 
CT scan (Figure 4).  
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Figure 4. CT scan of the brain of a patient with GBM. The tumor can be seen as a 
dark mass representing necrotic brain tissue in the right hemisphere, with irregular thick 
margins (Figure taken from Weerakkody, 2014). 
 
 The current modes of treatment for GBM are combinatory methods of surgery, 
radiation therapy, and chemotherapy. Despite the available treatment options, the 
prognosis of GBM is still poor, with the medial survival time post-diagnosis being 15 
months (Huse, 2013). While surgical resection is the first line of treatment, it is 
incredibly invasive and, due to the tumor’s tendency to be widely diffused, may not 
!16 
completely remove the cancerous cells. In most cases, residual tumor cells are still left 
after surgery, and can only be removed through radiation therapy or chemotherapy. 
Temozolomide (TMZ) is a DNA alkylating agent offered to GBM patients, which has 
increased the 5-year survival rate from a dismal 2% to 10% (Johnson, 2012). Despite the 
increased survival rate TMZ has been able to provide for GBM patients, it still 
demonstrates high inefficiency as its blood concentrations must remain low due to the 
toxic side effects of the drug, yet much of its therapeutic effects are inhibited by the BBB, 
preventing the drug from even entering the CNS.  
 Wei, in a preclinical study, demonstrated the use of FUS opening of the BBB to 
deliver TMZ to the brain was an improvement of current GBM treatments (Wei, 2013). 
In a three-part experiment, Wei first established that FUS was effective in the penetration 
of the BBB with Evans Blue dye.  
 The nonreactive Evans Blue dye would allow for easy visual confirmation of 
BBB opening by dying the brain tissue a bright blue once the BBB was penetrated. 
Figure 5 shows that brain tissue sonicated with FUS allows for a statistically significant 
increase in concentration of Evans Blue dye compared to unsonicated brains. Thus,!the!results!reveal!that!FUS!had!a!significant!effect!in!BBB!opening,!through!the!visualization!of!the!infiltration!of!Evans!Blue!dye!into!the!brain!tissue!of!rats!treated!with!FUS. 
   
 
!17 
 
Figure 5. Evans Blue dye concentration in the brains of rats with and without FUS 
treatment. The concentration of dye deposited in the brain without FUS treatment is 
significantly lower for both normal and tumor rats. FUS mediated BBB opening 
demonstrated a 3.8 times increase in dye concentration in normal rats (p < 0.001), and a 
2.1 times increase in dye concentration in tumor rats (p = 0.09) (Figure taken from Wei, 
2013). ! !!! In!the!second!arm!of!the!experiment,!control!(rats!not!receiving!any!treatment!procedures)!and!experimental!(rats!receiving!treatment!procedures)!rats!were!given!TMZ!orally!and!divided!into!without!FUSMtreatment!and!with!FUSMtreatment!groups.!The!concentration!of!TMZ!in!the!CSF!and!blood!plasma!was!then!measured!for!all!rats.!The!results!are!presented!in!Figure!6.!
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Figure 6. TMZ CSF and blood plasma concentration in the brains of rats with and 
without FUS treatment. a) TMZ concentration in CSF and blood plasma for rats treated 
with and without FUS. b) CSF/Plasma ratios derived from a) (Figure taken from Wei, 
2013). 
  
 The results demonstrate that while FUS treatment elevated CSF concentrations of 
TMZ, the differences were not significant (p = 0.225), and the blood plasma 
concentration differences between rats with and without FUS treatment did not differ 
significantly at all (p = 0.909). However, when the CSF/Plasma ratio was determined, it 
showed that the ratio was 22.7±3.9% in the group without FUS treatment and 
38.6±16.8% in the group with FUS treatment, showing that FUS opened the BBB, and 
increased the TMZ concentrations in brain tissues.  
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 In the final part of the experiment, the efficacy of combinatory TMZ and FUS 
treatment was evaluated by measuring the growth of tumor volume between day 10 and 
day 17, for control and experimental rats. The experimental rats were orally administered 
low (50 mg), medium (75 mg), and high (100 mg) doses of TMZ, and only rats 
undergoing medium doses of TMZ were concurrently treated with FUS.  The results are 
presented in Figure 7.  
 
 
Figure 7. Tumor progression amongst rats undergoing various level of TMZ and 
FUS treatment. a) Tumor volume (mm3) in rats of various treatments on day 10 and day 
17. Combined TMZ and FUS treatment was most effective in tempering tumor growth. b) 
Ratio of tumor volume from day 17 to day 10, derived from a) (Figure taken from Wei, 
2013). 
 
 The results clearly show that the combined TMZ and FUS treatment was far more 
effective in tempering tumor growth than the sole oral administration of TMZ. In 
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addition, a lower dosage of TMZ treatment in conjunction with FUS was able to produce 
slower tumor progression than just the higher TMZ dose alone, which reduces the 
necessity of taking higher doses of TMZ, a substance with toxic effects when 
administered in high quantities. Wei’s study shows that combined drug and FUS 
treatment has great potential in increasing drug CSF concentrations, increasing drug 
efficacy, and reducing the need for higher drug dosages.  
 A similar experiment conducted by Yang and colleagues revealed similar results 
(Yang, 2012). Also in an attempt to treat GBM using chemotherapy in conjunction with 
FUS, Yang explores the anti-tumor effects of another therapeutic agent, doxorubicin 
(DOX). DOX has been shown to be effective in the treatment and targeting of GBM, both 
extending the survival time as well as reducing the growth of the brain tumor (Lesniak, 
2005). However, the use of DOX is tempered by its tissue toxicity at the necessary 
therapeutic level, as well as the physiological barrier that the BBB poses.  
 Yang’s experiment involved the creation of liposomal DOX. Liposomes were 
created using hydrogenated soybean L- α-phosphatidylcholine, cholesterol, and 1,2-
distearoyl-sn-glycero- 3-phosphoethanolamine-N-[methoxy(polyethylene glycol)- 2000], 
extruded through polycarbonate membranes of a pore size of 0.05 µm, creating a 
suspension of liposomes. The liposome suspension was then mixed with DOX and 
intermittently shaken until the final product was liposomal DOX. The lipid bilayer of the 
liposomal DOX is meant to assist in the penetration of the BBB due to its high 
lipophilicity.  
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 Two groups of mice with GBM were used in the experiment—one group of mice 
was treated with combined liposomal DOX and FUS, while another group did not receive 
any treatment, acting as a control group. FUS treatment varied in acoustic power, from 
1.43 W, 2.86 W, and 4.29 W. Figure 8 shows that DOX concentrations in the brain is 
directly correlated with acoustic power, which demonstrate that level of BBB opening 
and infiltration of chemotherapies can be manipulated with acoustic power.  
 
!
Figure 8. Brain tissue DOX concentration amongst mice undergoing various level of 
liposomal DOX and FUS treatment. Higher DOX concentrations were seen in mice 
undergoing FUS treatment with higher acoustic powers (# p < 0.05; ** p < 0.01) (Figure 
taken from Yang, 2012). !
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 In addition, a group of mice received repeated sonication, and were sonicated a 
second time at an acoustic power of 2.86 W. Figure 9 shows the DOX concentrations in 
brain tissue in the surrounding tissues (contralateral brain), in the brain tumor of the non-
FUS treated GBM mice, as well as in the brain tumor of the double-sonicated GBM mice. 
There is a significantly higher concentration of DOX in the double-sonicated brain tumor, 
indicating that not only was FUS able to successfully penetrate the BBB, it was able to 
deliver more than 400% more therapeutics to the tumor tissue than the lack of FUS 
treatment. 
 
Figure 9. DOX concentration measurement amongst different brain tissue 
treatments. Compared with contralateral brain tissue and unsonicated brain tumor tissue, 
the repulsed brain tumor shows significantly higher concentrations of DOX (* p < 0.05; 
*** p < 0.001; ### p < 0.001) (Figure taken from Yang, 2012). 
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 Furthermore, the control and treated brains were imaged using magnetic 
resonance imaging (MRI), and the tumor margins assessed for growth. Figure 10 
demonstrates a greatly retarded tumor growth between the two groups, indicating the 
success of the dual FUS and DOX treatment in reducing tumor margins. 
 
Figure 10. MRI assessed brain tumor margins between the control group and the 
experimental group. a) Coronal view of the brain. b) Axial view of the brain. Both 
views show a significant reduction in the growth of the GBM tumor for the mice injected 
with liposomal DOX and double treated with FUS (Figure taken from Yang, 2012). 
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 An experiment conducted by Kovacs explores the longitudinal effects of GBM 
mice treated with DOX and subsequently sonicated with FUS (Kovacs, 2014). 
 Survival rates were assessed as mice that lost less than 15% of their body weights 
or did not developed neurological symptoms (characterized by behavioral deterioration or 
increased intracranial pressures). “Survival” is defined by the endured absence of these 
symptoms. 
 Figure 11 shows the cerebral DOX concentrations of the contralateral versus the 
sonicated tissue. The sonicated tissue has a significantly higher concentration of DOX 
compared to the contralateral tissue, emphasizing the success of the FUS facilitated BBB 
penetration by DOX (p = 0.0004).  
 
Figure 11. Cerebral DOX concentration in sonicated and unsonicated brain tissue. 
The unsonicated contralateral cerebral tissue shows significantly lower levels of DOX 
concentration than the sonicated and MB treated tissue (Figure taken from Kovacs, 
2014). !
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 The results of the survival analysis can be seen in Figure 12. The DOX and FUS 
treated mice saw a 68.18% higher average survival rate (p = 0.001) compared to DOX-
only treated mice and control mice, demonstrating the ability of FUS to not only aid in 
the local and specified delivery of therapeutics, but to affect the longitudinal survival 
patterns of mice with GBM. 
 The combinatory administration of DOX and FUS serve to delivery a higher 
concentration of DOX to the brain, which subsequently provides a higher survival rate for 
mice with GBM. This animal model holds great promise for current patients with GBM, 
potentially extending the life spans of patients post-diagnosis. 
 
 
Figure 12. Survival rates of the four groups of GBM mice, in days after tumor 
implantation. The untreated mice, as well as the DOX-only and FUS-only treated mice, 
demonstrate a quick drop in survival at the Day 22 mark. The DOX + FUS treated mice 
demonstrate a 68.18% longer survival rate (Figure taken from Kovacs, 2014). 
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 Through the experiments of Wei, Yang, and Kovacs, it can be proven that 
chemotherapy efficacy in the treatment of GBM can be significantly increased through 
the concurrent administration of FUS and chemotherapies (Wei, 2013; Yang, 2012; 
Kovacs, 2014). In addition to the advantage of temporary localized BBB opening for 
increased drug delivery to the brain, FUS treatment also allows for lowered drug doses, 
which decreases the harmful tissue side effects usually observed with the administration 
of drugs such as TMZ and DOX. FUS treatment also alleviates the physical burden for 
patients unable to undergo aggressive and invasive procedures, such as surgical resection 
of the tumor or intracranial drug injection.  
 Given the discouraging statistics regarding GBM survival lengths and treatment 
success rates, FUS treatment, conjointly administered with current treatment options, 
could be the key to a more optimistic prognosis and a higher survival rate for GBM 
patients.  
 
Alzheimer’s Disease 
 One of the most common forms of senile dementia, Alzheimer’s disease (AD) 
afflicts the elderly population above the age of 65, while early-onset AD can afflict 
people well before the age of 65. Early symptoms are characterized by short-term 
memory loss, absent mindedness, and confusion in new situations (Selkoe, 2001). In late 
stage AD, patients lose self-awareness, lose cognitive functions and abilities, and 
eventually lead to death. In the United States alone, there are an estimated 5.2 million 
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people with AD in 2014, and it is the 6th leading cause of death (Alzheimer’s Association, 
2014).  
 Physiologically, it is caused by the irregular cleavage of the neuronal 
transmembrane amyloid precursor protein (APP) (Selkoe, 2001). In the normal pathway, 
enzymes alpha-secretase and gamma-secretase cleave APP into the fragment sAPPα and 
another fragment that remains in the neuron (Figure 13).  
 
 
Figure 13. Normal cleavage of APP by alpha-secretase and gamma-secretase. In a 
normal pathway, the neuronal transmembrane protrein APP is cleaved into sAPPα by the 
enzymes alpha-secretase and gamma-secretase (Figure taken from Rodgers, 2008). 
 
 However, in the case of AD, beta-secretase instead cleaves APP, into the 
fragment sAPPβ, which is released form the cell. Gamma-secretase then cleaves the 
resulting fragment, and releases a free beta-amyloid (Aβ) peptide (Figure 14).  
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Figure 14. Abnormal cleavage of APP by beta-secretase and gamma-secretase. In an 
abnormal pathway, the neuronal transmembrane protrein APP is cleaved into sAPPβ and 
Aβ peptide by the enzymes beta-secretase and gamma-secretase (Figure taken from 
Rodgers, 2008). 
 The free Aβ peptides begin to aggregate and create oligomers, which clump with 
other oligomers to create extracellular Aβ plaques. These plaques interfere with cerebral 
cells and synapses, preventing normal brain functions, which lead to the characteristic 
symptoms of AD (Figure 15).  
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Figure 15. The biochemical pathway of Alzheimer’s disease. The transmembrane 
protein APP is improperly cleaved and leads to the synthesis of Aβ plaques (Figure taken 
from Rodgers, 2008). 
 While anti- Aβ antibodies have been proven to be efficacious against Aβ plaques, 
the BBB poses as a formidable obstacle against their delivery into the cerebral cortex 
(Kotilinek, 2002). The size and hydrophilicity of the anti-Aβ antibodies inhibit them from 
passing the BBB, thus preventing the CSF concentrations of the anti-Aβ antibodies from 
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reaching therapeutic levels. Procedures involving direct delivery of anti-Aβ antibodies to 
the cortex have been developed, but the invasive and aggressive nature of the procedure 
makes this an impractical option for most elderly patients of AD (Wilcock, 2003).  
 Jordao’s experiment combining anti-Aβ antibodies with MRI-guided FUS 
addresses both these limitations by avoiding an invasive therapeutic delivery procedure 
and creating a method of bypassing the BBB (Jordao, 2013).  
 In this experiment, mice exhibiting abundant plaque load were injected with a MB 
and anti-Aβ antibody mixture of immunoglobulin G (IgG) and immunoglobulin M (IgM), 
along with an MRI contrasting agent. MRI-guided FUS was administered to the right 
cortex of each mouse, with the MRI acting as a targeting mechanism to allow for precise 
positioning and target control. With each mouse’s left cortex acting as a control, the 
treated right cortex demonstrates the effects of FUS in aiding IgG and IgM delivery 
(Figure 16).  
 Jordao’s results demonstrate that not only was MRI guided FUS capable of aiding 
the delivery of the anti-Aβ antibodies into the cerebral cortex, the increased presence of 
the IgG and IgM was directly able to decrease plaque number, size, and total surface area 
of the plaques.  
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Figure 16. The effects of MRI-guided FUS on Aβ plaque pathology. A) Visible plaque 
reduction in histologic stain comparisons of the right and left cortex. B) Mean plaque 
size, C) total surface area of the plaques, and D) number of plaques have also been 
reduced. E) At the right cortex, looking at the plaques treated with FUS and antibodies, 
F) IgG and G) IgM are found to be bound to the plaques. H) At the left cortex, looking at 
the plaque treated with antibodies but no FUS, I) IgG is found only slightly bound to the 
plaque, and J) no IgM is found bound to the plaque (Figure taken from Jordao, 2013). 
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  Histological staining for each anti-Aβ antibody (IgG and IgM) was able to 
demonstrate the heightened presence of each antibody in the right cortex, which was 
treated with MRI guided FUS, compared to the left cortex, which was left untreated 
(Figure 17).  The darker stain in the right cortex clearly demonstrates that MRI guided 
FUS was able to open the BBB and allow for higher antibody infiltration into the brain 
tissue.  
 
A 
 
 
 
B 
 
 
Figure 17. Histological staining of cortex treated with MRI guided FUS and 
untreated cortex. A) Staining for IgG presence in the cortex. B) Staining for IgM 
presence in the cortex (Figure taken from Jordao, 2013). 
  
 Currently, AD is without treatment, and its high prevalence in the global elderly 
population emphasizes a pressing need to develop a treatment that doesn’t just combat 
symptoms. As a noninvasive and localized procedure, FUS allows for specified and 
targeted delivery of therapeutics to the brain, which is a distinct advantage over other 
treatment options such as surgery and oral medications. 
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Tumor Metastasis in CNS 
 Frequently in cases of advanced cancer stages, patients will develop cancer 
metastasis in the CNS, which remains impervious to current cancer chemotherapies and 
can be a point of cancer relapse. For example, 10-16% of breast cancer patients develop 
CNS metastasis, and the five-year survival rate of breast cancer patients with CNS 
metastasis is a feeble 1.3% (Pienkowski, 2010). The high mortality rates for patients with 
tumor metastasis in the CNS is due to the low efficacy of chemotherapies in the CNS, as 
the BBB acts as a barrier against drug entry.  
 Trastuzumab (herceptin) has been used with success in patients with breast 
cancer, but has not been of benefit for breast cancer patients with CNS metastasis. In a 
study conducted by Park, FUS is used to open the BBB to deliver trastuzumab to the 
brains of rats, in a breast cancer brain metastasis model (Park, 2012). To achieve the 
breast cancer brain metastasis model, 41 rats were inoculated by direct surgical 
implantation of HER2-positive human breast ductal carcinoma cells into the right frontal 
lobe of the brain. The tumors were subsequently monitored with MRI for 14 days to 
ensure proper growth to 2-3mm in size. In rats that received FUS, MBs were also 
intravenously administered to facilitate BBB penetration. 
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Figure 18. Tumor volume analysis for each breast cancer brain metastasis 
experimental group. a) Tumor volume over time for each experimental group. b) Tumor 
volume normalized to tumor volume at week 1. c) Measurement for each rat’s normalized 
tumor volume at week 7 (Figure taken from Park, 2012). 
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 Over the subsequent 13 weeks, each rat’s tumor volume was measured with MRI 
and analyzed (Figure 18). The results show that the concurrent trastuzumab and FUS 
treatment was significantly more efficacious in reducing tumor volume over the weeks (p 
< 0.05). Rats that received only FUS treatment and rats that received only trastuzumab 
treatment observed tumor volume growth similar to rats that received no treatment at all. 
Only rats that received concurrent trastuzumab and FUS treatment were able to observe a 
decline in tumor volume, and 4 rats in the this group appears to have complete tumor 
regression as measured with MRI. At the end of the study (week 13), only 4 rats 
survived, and they were all from the trastuzumab and FUS treatment group.  
 Looking at the survival rates for up to 83 days, mice that did not receive any 
treatment had the lowest survival rate, and had all died by day 80 (Figure 19). However, 
the trastuzumab and FUS treatment group were able to live the longest of the 4 groups, at 
17% longer than the trastuzumab only group, and 32% longer than the group without 
treatment. These results demonstrate that FUS was able to increase therapeutic delivery 
to the tumor region, as well as significantly influence the survival rates of the 
combinatory FUS and trastuzumab treatment group. 
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Figure 19. Survival rates for each breast cancer brain metastasis experimental 
group, up to 83 days. The group without treatment had the lowest survival rate, while 
the trastuzumab and FUS treatment group was the longest surviving, at 32% longer than 
the group without treatment (Figure taken from Park, 2012). 
 
Gene Therapy 
 Gene therapy holds great potential in the treatment of genetic CNS diseases, such 
as Parkinson’s and AD, and is in the clinical trial stages of research and development 
(Christine, 2009; Mandel, 2010). Recombinant adeno-associated viral (rAAV) vectors are 
advantageous in its lack of pathogenicity, low immunopathology, continual removal of 
viral genes, and its longitudinal effects (Mingozzi, 2011).  
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 The principle is illustrated in Figure 20, in which a new genome is introduced into 
a cell via an adenoviral vector. The viral vector contains an engineered genome that 
includes a new gene, to be expressed by the cell receiving the vector. The adenoviral 
vector binds to the cell membrane, undergoes endocytosis, the viral vector is broken 
down, and the gene is injected into the nucleus, where it proceeds to be translated.  
 
 
Figure 20. Principle of gene therapy using an adenovirus vector. The adenovirus 
vector contains the modified DNA, which the cell proceeds to uptake. The vector is 
broken down, the DNA injected into the cell nucleus, and the packaged DNA is 
expressed (Figure taken from U.S. National Library of Medicine, 2014). 
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 Gene therapy holds much promise and power for current untreatable genetic 
illnesses, as instead of treating symptoms, it would be able to direct the treatment to the 
genetic source and rectify the wayward gene. In addition, its persistence would eliminate 
the need for constant treatments or procedures. In the treatment of CNS diseases, gene 
therapies are tempered by the inaccessibility of the CSF to viral vectors due to the 
impenetrability of the BBB.  
 In an experiment conducted by Hsu, rAAV vectors were directly delivered to the 
brain using MB mediated FUS (Hsu, 2013). In this study, mice were injected with 
AAV2-GFP (adeno-associated virus-green fluorescence protein). GFP expression would 
not only demonstrate the success of the BBB opening, but the delivery of the vector to 
the target and its subsequent expression. Bright green regions on the brain slices when 
seen under the fluorescent microscope would easily visually affirm GFP expression.  
 Experimental mice received a MB facilitated FUS treatment, guided by MRI. The 
mice that received both vector and FUS treatment were gradually sacrificed on a weekly 
basis over the course of 6 weeks to observe longitudinal GFP expression (Figure 21). 
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Figure 21. Longitudinal GFP expression in 4 experimental groups of mice receiving 
rAAV vector treatment with FUS. a) The top panel demonstrates the target region of 
the brain and the bottom panel demonstrates the contralateral brain region, acting as 
control. b) Measurement of GFP signal increase at each point of the longitudinal study 
(Figure taken from Hsu, 2013). 
 
 In each experimental group, the target region of the brain is demonstrated on the 
top panel, and the contralateral brain region is on the bottom panel, acting as control. In 
both the group that only received FUS treatment and the group that only received viral 
!40 
vector treatment, no GFP expression was visualized in both the target and control region. 
In the case of the FUS only treatment, there is a lack of AAV2-GFP gene to even express 
the GFP fluorescence. In the AAV2-GFP only treatment, the absence of fluorescence 
demonstrates that without FUS, there is no BBB opening, which prevents the vector from 
being delivered to the brain, thus no GFP was expressed in both target and control 
regions.  
 In the group receiving direct cranial injections of AAV2-GFP, the target region is 
highly fluorescent, and the control region without fluorescence. In the group receiving the 
viral vector concurrently with FUS treatment, there is a steady increase in GFP 
expression from day 7 to day 21, which is a peak, then a decrease in fluorescence until 
the end of the longitudinal study. The GFP expression in the group received dual 
treatment at the peak (day 21) is comparable to the GFP expression in the group that 
received direct cranial injection (122.8% increase in fluorescence compared to 148.7% 
increase), denoting that conjoined vector and FUS treatment can be comparably effective 
as direct cranial injection of the viral vector.  
 The results from this study show that FUS facilitated BBB opening can not only 
directly deliver viral vectors to the cranial target region, but can also bring about 
successful gene expression. This noninvasive manner of drug administration is 
comparable in efficacy to direct cranial injection of viral vectors, pairing high therapeutic 
effect with low levels of procedural aggression.!  
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DISCUSSION 
 
Due to the stagnant nature of current CNS disorder treatments and the pressing 
need for more advancement in the field of CNS disorder therapeutics, this study poses to 
explore the potential of FUS as a key role in the future treatments of CNS disorders.  
In the treatment of GBM, Wei was able to demonstrate the successful delivery of 
the chemotherapy, TMZ, to the area of the tumor while using combinatory FUS and 
therapeutics (Wei, 2013). Not only was Wei able to use lower doses of TMZ to prevent 
tissue toxicity, the study showed that there was a statistically significant higher 
concentrations of TMZ in the sonicated tumor tissue than the untreated tissue, which also 
lead to a lower rate of tumor growth in the sonicated rats.  
Yang’s experiment utilized DOX in the treatment of GBM, and similarly 
established that FUS was able to significantly boost DOX concentrations in the brain, 
which lead to decreased tumor margins (Yang, 2012). The double sonication of the tumor 
in this study further emphasized the efficacy of the FUS—when the cerebral cortex was 
double sonicated, the DOX concentration was able to increase to over 400% the levels of 
that in the unsonicated mice, suggesting that repeated sonication may be a valid course of 
action for patients who cannot tolerate high doses of chemotherapies.  
Kovac’s experiment also analyzed the combinatory effects of DOX and FUS in 
the treatment of GBM, but looked further at the longitudinal effects of the dual treatment 
on survival rate (Kovac, 2014). He found that not only was FUS able to deliver DOX 
effectively to the GBM tumor, it was able to significantly increase the survival rates of 
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the experimental mice by 68%. In this study, the success of the DOX drug delivery was 
directly correlated with increased survival rates, illustrating the powerful potential of 
FUS in the treatment of brain tumors.  
In the field of AD treatments, Jordao’s experiment combines anti-Aβ antibodies 
with FUS (Jordao, 2013). Due to the hydrophilic nature and large size of anti-Aβ 
antibodies, they were unable to enter the brain and execute therapeutic effect due to BBB 
impermeability. When combined with FUS, and with MRI acting as a targeting guide, the 
anti-Aβ antibodies were able to be delivered to the cerebral cortex. Through histological 
analysis, Jordao was able to ascertain that the Aβ plaques, which are primary contributors 
to AD pathology, decreased in size, number, and surface area after treatment with anti-Aβ 
antibodies. With FUS as a tool, there could be a more optimistic outlook for patients with 
AD, one with more aggressive forms of treatment.  
Park’s experiment addresses the metastasis of other tumor cells into the CNS, 
such as in the instance of breast cancer metastasis (Park, 2012). Park researched the 
longitudinal impact of combined FUS and trastuzumab treatment, and observed that it 
was able to greatly reduce tumor size, as well as increase survival rates up to 32%. A 
number of rats in this experiment also experienced complete tumor remission, an 
encouraging prospect in the treatment of tumor metastasis into the CNS.  
In the use of gene therapy to treat genetic CNS disease, such as Parkinson’s and 
AD, Hsu used rAAV vectors containing a AAV2-GFP gene to test the ability of FUS 
ability to deliver rAAV vectors, then the ability of the delivered vectors to successfully 
produce GFP in the cerebral cortex. The results of the experiment demonstrate that FUS 
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was capable of delivering the viral vector, and the viral vector was able to successfully 
express the GFP gene. The GFP expression from FUS-facilitated BBB opening was 
comparable to the level of GFP expression from direct intracranial injection of AAV2-
GFP into the brain, which prove that FUS is highly efficacious in its localized delivery of 
therapeutics.  From!the!FUS!studies!conducted,!the!results!demonstrate!that!the!procedure!is!able!to!significantly!increase!drug!concentrations!in!brain,!increase!survival!rates!of!the!animal!models,!decrease!tumor!growth,!and!decrease!tumor!margins!and!volume.!The!potential!and!power!of!FUS!should!be!further!explored!as!the!future!of!CNS!disorder!treatments.!!There!are!numerous!distinct!advantages!of!FUSMfacilitated!BBB!opening!over!other!methods!of!CNS!disorder!treatments.!First,!its!noninvasive!nature!makes!it!a!safer!alternative!to!surgery,!especially!for!elderly!or!more!weakened!patients!unable!to!undergo!an!aggressive!procedure!such!as!brain!surgery.!Second,!its!localized!treatment!allows!for!specific,!targeted!drug!delivery,!which!can!reduce!unnecessary!tissue!damage!and!prevent!drug!dispersion.!Third,!the!application!of!FUS!reduces!the!doses!of!drugs!necessary!to!reach!therapeutic!levels,!as!its!targeted!delivery!directs!its!effects.!This!would!lower!the!chances!of!toxicity,!especially!in!cases!in!which!the!chemotherapy!is!highly!damaging!to!systemic!tissues.!Finally,!the!use!of!FUS!would!wide!the!options!of!drug!development!for!CNS!disorders,!as!therapeutics!are!no!longer!limited!to!small,!hydrophobic!molecules.!Antibodies,!viral!vectors,!and!large!chemotherapeutics!can!all!be!explored!as!potential!drugs!treatment!options.!
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CONCLUSION/ FUTURE DIRECTION 
!! Despite!the!advantages!FUS!can!bring!to!CNS!treatments,!there!is!still!much!to!improve!on!and!consider.!Primarily,!the!procedure!as!it!applied!to!BBB!opening!is!still!in!its!beginning!stages!of!research,!and!there!are!still!many!points!to!address.!Currently,!some!researchers!increase!the!BBB!opening!efficiency!by!using!MBs,!and!guiding!the!FUS!with!MRI!to!help!targeting.!However,!there!could!be!better!methods!for!increasing!BBB!permeability,!one!that!does!not!include!MB!injections!and!double!sonication.!The!process!could!be!further!researched!to!reach!a!more!streamlined!and!standardized!process!for!FUSMfacilitated!BBB!opening.!!!! Further!research!should!also!be!conducted!in!the!longitudinal!safety!and!effects!of!temporary!BBB!opening,!in!the!assessment!of!the!extent!of!neuronal!damage,!cell!necrosis,!and!any!ensuing!behavioral!changed!from!this!procedure.!!Also!to!be!considered!is!whether!the!temporary!BBB!opening!poses!a!danger!to!the!CNS!for!any!circulating!foreign!materials!or!pathogens!in!body!that!unintentionally!enters!the!CNS!during!the!treatment.!Furthermore,!the!use!of!FUS!in!the!treatment!of!a!wider!range!of!CNS!disorders!should!be!investigated,!such!as!encephalitis,!epilepsy,!Tourette’s,!Huntington’s,!and!multiple!sclerosis.!!Current!animal!models!of!FUSMfacilitated!BBB!opening!are!all!rodents;!it!would!be!beneficial!to!attempt!a!study!on!nonhuman!primates,!to!analyze!its!effects!on!an!animal!with!a!thicker!cranium.!The!acoustic!pressures!would!change!in!order!to!penetrate!the!BBB,!and!the!ensuing!tissue!damage!could!be!more!significant.!!
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Due!to!the!novel!and!experimental!nature!of!this!procedure,!there!are!many!issues!to!be!considered!and!further!researched,!and!it!may!be!many!years!before!the!treatment!can!reach!clinical!stages.!However,!the!advantages!that!FUS!offers!to!the!field!of!CNS!disorders!grant!it!a!key!role!in!the!future!of!CNS!treatments,!potentially!helping!CNS!treatment!options!to!improve!in!efficacy!and!safety.!
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